Navigation Links
Sea lice treatment increased in Norwegian fish breeding in 2009
Date:3/16/2010

Last year, increased resistance to sea lice treatments such as the pyrethroids cypermethrin and deltamethrin, as well as emamectine, was observed. Pyrethroid use still increased from 2008 to 2009, although use of emamectine reduced significantly. Older sea lice treatments are being used again due to resistance problems, e.g. azametiphos, diflubenzuron and teflubenzuron. Hydrogen peroxide, which has not been used since 1997, was also used again in 2009, mainly under controlled conditions in wellboats.

The increase in antibacterial sales from 2008-2009 was marginal and, when seen in relation to the biomass of bred fish, the usage is very low. Prescription-based statistics from the Norwegian Food Safety Authority for 2000-2008 show that antibacterials have been increasingly used in the treatment of newer breeding fish species, especially cod. For this period, the increase in the use in cod was positively correlated to the increase in biomass of cod produced. Data for sales per fish species for 2009 are not yet available.

Anthelmintics have shown an annual reduction in sales since 2004 and fungicides are back to 2008 levels.

The figures are based on sales from wholesalers to pharmacies and from feed mills to breeders.


'/>"/>

Contact: Irene Litleskare
Irene.Litleskare@fhi.no
Norwegian Institute of Public Health
Source:Eurekalert

Page: 1

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. A new radiation therapy treatment developed for head and neck cancer patients
3. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
4. Presence of gene mutation helps guide thyroid cancer treatment
5. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
6. New genetic research into nicotine addiction shows promise for personalized treatment
7. Interleukin-8, key marker for colorectal cancer treatment
8. New class of drug offers hope to treatment-resistant AIDS patients
9. Paradigm shift in Alzheimerss research: new treatments
10. New research on structure of bones raises questions for treatment of osteoporosis
11. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). Cash ... --> --> January to December ... 1,142% compared with 2014. Gross margin was 43% (31). ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... Potentials of that Rising Market Are you ... new analysis forecasts revenues for checkpoint inhibitors. Visiongain,s ... world market, submarket, product and national level. ... Instead discover what progress, opportunities and revenues those ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... , February 8, 2016 ... ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular ... CE Mark its Chlamydia trachomatis (CT) test to be launched ... the IVD Directive (98/79/EC), the CT test is now cleared ... --> The launch of the io® CT ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, Abby Mitchell, ... Excellence in Education Sponsors Teacher Training Program , Bite of Science Dinner Event ... Center for Excellence in Education (CEE) will sponsor a Bite of Science professional ...
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical industry ... a host of launch activities including the identification and ... launch activity is especially high in the oncology therapeutic ... Best Practices and the Role of Medical Affairs in ... focused on oncology therapies find better ways to utilize ...
(Date:2/5/2016)... February 5, 2016 Amarantus BioScience ... company focused on developing products for Regenerative Medicine, Neurology ... Pediatric Disease Designation (RPDD) from the US Food and ... MANF. MANF was previously granted orphan drug designation (ODD) ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
Breaking Biology Technology: